257 related articles for article (PubMed ID: 18388156)
1. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.
Keystone E; Emery P; Peterfy CG; Tak PP; Cohen S; Genovese MC; Dougados M; Burmester GR; Greenwald M; Kvien TK; Williams S; Hagerty D; Cravets MW; Shaw T
Ann Rheum Dis; 2009 Feb; 68(2):216-21. PubMed ID: 18388156
[TBL] [Abstract][Full Text] [Related]
2. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate.
Cohen SB; Keystone E; Genovese MC; Emery P; Peterfy C; Tak PP; Cravets M; Shaw T; Hagerty D
Ann Rheum Dis; 2010 Jun; 69(6):1158-61. PubMed ID: 20439295
[TBL] [Abstract][Full Text] [Related]
3. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.
Tak PP; Rigby W; Rubbert-Roth A; Peterfy C; van Vollenhoven RF; Stohl W; Healy E; Hessey E; Reynard M; Shaw T
Ann Rheum Dis; 2012 Mar; 71(3):351-7. PubMed ID: 22012969
[TBL] [Abstract][Full Text] [Related]
4. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
Keystone EC; Kavanaugh AF; Sharp JT; Tannenbaum H; Hua Y; Teoh LS; Fischkoff SA; Chartash EK
Arthritis Rheum; 2004 May; 50(5):1400-11. PubMed ID: 15146409
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
6. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study.
Keystone EC; Cohen SB; Emery P; Kremer JM; Dougados M; Loveless JE; Chung C; Wong P; Lehane PB; Tyrrell H
J Rheumatol; 2012 Dec; 39(12):2238-46. PubMed ID: 23027887
[TBL] [Abstract][Full Text] [Related]
7. MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.
Peterfy C; Emery P; Tak PP; Østergaard M; DiCarlo J; Otsa K; Navarro Sarabia F; Pavelka K; Bagnard MA; Gylvin LH; Bernasconi C; Gabriele A
Ann Rheum Dis; 2016 Jan; 75(1):170-7. PubMed ID: 25355728
[TBL] [Abstract][Full Text] [Related]
8. Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients.
Aletaha D; Alasti F; Smolen JS
Ann Rheum Dis; 2013 Jan; 72(1):7-12. PubMed ID: 22915619
[TBL] [Abstract][Full Text] [Related]
9. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results.
Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM
J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)).
Emery P; Deodhar A; Rigby WF; Isaacs JD; Combe B; Racewicz AJ; Latinis K; Abud-Mendoza C; Szczepanski LJ; Roschmann RA; Chen A; Armstrong GK; Douglass W; Tyrrell H
Ann Rheum Dis; 2010 Sep; 69(9):1629-35. PubMed ID: 20488885
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial.
Mease PJ; Cohen S; Gaylis NB; Chubick A; Kaell AT; Greenwald M; Agarwal S; Yin M; Kelman A
J Rheumatol; 2010 May; 37(5):917-27. PubMed ID: 20194448
[TBL] [Abstract][Full Text] [Related]
13. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.
Takeuchi T; Yamanaka H; Ishiguro N; Miyasaka N; Mukai M; Matsubara T; Uchida S; Akama H; Kupper H; Arora V; Tanaka Y
Ann Rheum Dis; 2014 Mar; 73(3):536-43. PubMed ID: 23316080
[TBL] [Abstract][Full Text] [Related]
15. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.
Smolen JS; Han C; van der Heijde DM; Emery P; Bathon JM; Keystone E; Maini RN; Kalden JR; Aletaha D; Baker D; Han J; Bala M; St Clair EW;
Ann Rheum Dis; 2009 Jun; 68(6):823-7. PubMed ID: 18593759
[TBL] [Abstract][Full Text] [Related]
16. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
[TBL] [Abstract][Full Text] [Related]
17. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
Humby F; Durez P; Buch MH; Lewis MJ; Rizvi H; Rivellese F; Nerviani A; Giorli G; Mahto A; Montecucco C; Lauwerys B; Ng N; Ho P; Bombardieri M; Romão VC; Verschueren P; Kelly S; Sainaghi PP; Gendi N; Dasgupta B; Cauli A; Reynolds P; Cañete JD; Moots R; Taylor PC; Edwards CJ; Isaacs J; Sasieni P; Choy E; Pitzalis C;
Lancet; 2021 Jan; 397(10271):305-317. PubMed ID: 33485455
[TBL] [Abstract][Full Text] [Related]
18. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing.
Smolen JS; van der Heijde DM; Aletaha D; Xu S; Han J; Baker D; St Clair EW
Ann Rheum Dis; 2009 Oct; 68(10):1535-40. PubMed ID: 18957487
[TBL] [Abstract][Full Text] [Related]
19. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
Barrera P; van der Maas A; van Ede AE; Kiemeney BA; Laan RF; van de Putte LB; van Riel PL
Rheumatology (Oxford); 2002 Apr; 41(4):430-9. PubMed ID: 11961174
[TBL] [Abstract][Full Text] [Related]
20. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
